Table 1.
Participants’ characteristics
| Characteristics | Control group n = 150 |
Intervention group n = 152 |
|---|---|---|
| n (%) | n (%) | |
| General characteristics | ||
| Sex, female | 98 (65.3) | 109 (71.7) |
| Age, mean (SD) | 60.0 (9.2) | 59.0 (9.5) |
| Educational level | ||
| Elementary school or less | 21 (14.0) | 19 (12.5) |
| Secondary school | 36 (24.0) | 43 (28.3) |
| High school | 62 (41.3) | 60 (39.5) |
| University degree | 31 (20.7) | 30 (19.7) |
| Clinical characteristics | ||
| Body mass index (kg/m2), mean (SD) | 30.3 (5.7) | 29.4 (4.7) |
| Nutritional status | ||
| Normal weight (BMI: 18.5–24.9 kg/m2) | 21 (14.0) | 28 (18.4) |
| Overweight (BMI: 25.0–29.9 kg/m2) | 63 (42.0) | 61 (40.1) |
| Obesity (BMI ≥ 30 kg/m2) | 66 (44.0) | 63 (41.5) |
| Time since diabetes diagnosis (years), mean (SD) | 14.3 (9.3) | 14.0 (8.1) |
| Baseline pharmacologic treatment | ||
| Insulin**** | 73 (48.7) | 110 (72.4) |
| Metformin | 115 (76.7) | 123 (80.9) |
| Glibenclamide** | 53 (35.3) | 32 (21.1) |
| Pioglitazone | 6 (4.0) | 10 (6.6) |
| Linagliptin | 46 (30.7) | 56 (36.8) |
| Baseline HbA1c (%), mean (SD)*** | 9.3 (1.0) | 9.8 (1.4) |
| Modifications to treatment following the baseline evaluation* | 99 (66.0) | 74 (48.7) |
| Loss of follow-up | 12 (8.0) | 22 (14.5) |
| Missing CGM information at three-month evaluation | 14 (9.2%) | |
SD Standard deviation
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001